The known indications for erlotinib, whose target genes are ABCG2 and EGFR, are colon cancer, glioma, head and neck cancer, etc. Similarly, the known indication for olaparib, whose target genes are PARP1 and PARP2, is ovarian cancer (Fig. 5a). Here, PARP2 is linked to malignant colon neoplasm.